✦ LIBER ✦

P1216 EFFICACY AND SAFETY OF SIMEPREVIR PLUS PEG-INTERFERON/RIBAVIRIN THERAPY IN PATIENTS WITH HCV GENOTYPE 1 – COMPARISON WITH TELAPREVIR PLUS PEG-INTERFERON/RIBAVIRIN THERAPY AND PEG-INTERFERON/RIBAVIRIN THERAPY

✍ Scribed by Nakajima, T.; Kimura, M.; Arakawa, T.; Kuwata, Y.; Ozeki, I.; Sato, T.; Ohmura, T.; Hige, S.; Karino, Y.; Toyota, J.

Book ID: 122150840
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 59 KB
Volume: 60
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(14)61376-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison between combination therapy w

Comparison between combination therapy with peg-interferon alfa-2A plus ribavirin and peg-interferon alfa-2B plus ribavirin in the treatment of chronic hepatitis C

✍ M. Capanni; M.R. Biagini; S. Nanni; E. Lorefice; M. Paci; M.C. Benini; E. Gai; A 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Efficacy of interferon plus ribavirin th

Efficacy of interferon plus ribavirin therapy in patients with relapsed HCV

✍ C. Petrogiannopoulos; A.K. Zacharof; L. Petrogiannopoulos; P. Paziouros 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 104 KB

HCV substitutions and IL28B polymorphism

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

✍ Hayes, C. N.; Kobayashi, M.; Akuta, N.; Suzuki, F.; Kumada, H.; Abe, H.; Miki, D 📂 Article 📅 2010 🏛 BMJ Publishing Group 🌐 English ⚖ 224 KB

Estimates of HCV-1 Patients Attaining RV

Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin

✍ Andriulli, A.; Iacobellis, A.; Valvano, M. R.; Spirito, F.; Ippolito, A.; Bossa, 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 572 KB

Influence of HCV genotype 1 subtypes on

Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy

✍ F. Nicot; L. Alric; K. Barange; S. Métivier; J.M. Dramard; J.M. Combis; B. Casta 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

## Abstract New factors that influence the viral response in HCV non‐genotype 2/3 patients must be identified in order to optimize anti‐HCV treatment. This multicenter prospective study evaluates the influence of HCV variability and pharmacological parameters on the virological response of these pa

Ribavirin dosage in patients with HCV ge

Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon α-2b and ribavirin

✍ A. MANGIA; O. DALGARD; N. MINERVA; H. VERBAAN; D. BACCA; H. RING-LARSEN; M. COPE 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB